cHCC-CCA: Consensus terminology for primary liver carcinomas with both hepatocytic and cholangiocytic differentation

Elizabeth Brunt; Shinichi Aishima; Pierre Alain Clavien; Kathryn Fowler; Zachary Goodman; Gregory Gores; Annette Gouw; Alex Kagen; David Klimstra; Mina Komuta; Fukuo Kondo; Rebecca Miksad; Masayuki Nakano; Yasuni Nakanuma; Irene Ng; Valerie Paradis; Young Nyun Park; Alberto Quaglia; Massimo Roncalli; Tania Roskams; Michiie Sakamoto; Romil Saxena; Christine Sempoux; Claude Sirlin; Ashley Stueck; Swan Thung; W. M.S. Tsui; Xin Wei Wang; Aileen Wee; Hirohisa Yano; Matthew Yeh; Yoh Zen; Jessica Zucman-Rossi; Neil Theise

doi:10.1002/hep.29789

cHCC-CCA: Consensus terminology for primary liver carcinomas with both hepatocytic and cholangiocytic differentation

Elizabeth Brunt, Shinichi Aishima, Pierre Alain Clavien, Kathryn Fowler, Zachary Goodman, Gregory Gores, Annette Gouw, Alex Kagen, David Klimstra, Mina Komuta, Fukuo Kondo, Rebecca Miksad, Masayuki Nakano, Yasuni Nakanuma, Irene Ng, Valerie Paradis, Young Nyun Park, Alberto Quaglia, Massimo Roncalli, Tania RoskamsMichiie Sakamoto, Romil Saxena, Christine Sempoux, Claude Sirlin, Ashley Stueck, Swan Thung, W. M.S. Tsui, Xin Wei Wang, Aileen Wee, Hirohisa Yano, Matthew Yeh, Yoh Zen, Jessica Zucman-Rossi, Neil Theise

Gastroenterology and Hepatology

Research output: Contribution to journal › Article › peer-review

112 Scopus citations

Abstract

Primary liver carcinomas with both hepatocytic and cholangiocytic differentiation have been referred to as “combined (or mixed) hepatocellular-cholangiocarcinoma.” These tumors, although described over 100 years ago, have attracted greater attention recently because of interest in possible stem cell origin and perhaps because of greater frequency and clinical recognition. Currently, because of a lack of common terminology in the literature, effective treatment and predictable outcome data have been challenging to accrue. This article represents a consensus document from an international community of pathologists, radiologists, and clinicians who have studied and reported on these tumors and recommends a working terminology for diagnostic and research approaches for further study and evaluation. Conclusion: It is recommended that diagnosis is based on routine histopathology with hematoxylin and eosin (H&E); immunostains are supportive, but not essential for diagnosis. (Hepatology 2018;68:113-126).

Original language	English (US)
Pages (from-to)	113-126
Number of pages	14
Journal	Hepatology
Volume	68
Issue number	1
DOIs	https://doi.org/10.1002/hep.29789
State	Published - Jul 2018

ASJC Scopus subject areas

Hepatology

Access to Document

10.1002/hep.29789

Cite this

Brunt, E., Aishima, S., Clavien, P. A., Fowler, K., Goodman, Z., Gores, G., Gouw, A., Kagen, A., Klimstra, D., Komuta, M., Kondo, F., Miksad, R., Nakano, M., Nakanuma, Y., Ng, I., Paradis, V., Nyun Park, Y., Quaglia, A., Roncalli, M., ... Theise, N. (2018). cHCC-CCA: Consensus terminology for primary liver carcinomas with both hepatocytic and cholangiocytic differentation. Hepatology, 68(1), 113-126. https://doi.org/10.1002/hep.29789

Brunt, E, Aishima, S, Clavien, PA, Fowler, K, Goodman, Z, Gores, G, Gouw, A, Kagen, A, Klimstra, D, Komuta, M, Kondo, F, Miksad, R, Nakano, M, Nakanuma, Y, Ng, I, Paradis, V, Nyun Park, Y, Quaglia, A, Roncalli, M, Roskams, T, Sakamoto, M, Saxena, R, Sempoux, C, Sirlin, C, Stueck, A, Thung, S, Tsui, WMS, Wang, XW, Wee, A, Yano, H, Yeh, M, Zen, Y, Zucman-Rossi, J & Theise, N 2018, 'cHCC-CCA: Consensus terminology for primary liver carcinomas with both hepatocytic and cholangiocytic differentation', Hepatology, vol. 68, no. 1, pp. 113-126. https://doi.org/10.1002/hep.29789

@article{5de322aa812447feba6d24578b1c4d72,

title = "cHCC-CCA: Consensus terminology for primary liver carcinomas with both hepatocytic and cholangiocytic differentation",

abstract = "Primary liver carcinomas with both hepatocytic and cholangiocytic differentiation have been referred to as “combined (or mixed) hepatocellular-cholangiocarcinoma.” These tumors, although described over 100 years ago, have attracted greater attention recently because of interest in possible stem cell origin and perhaps because of greater frequency and clinical recognition. Currently, because of a lack of common terminology in the literature, effective treatment and predictable outcome data have been challenging to accrue. This article represents a consensus document from an international community of pathologists, radiologists, and clinicians who have studied and reported on these tumors and recommends a working terminology for diagnostic and research approaches for further study and evaluation. Conclusion: It is recommended that diagnosis is based on routine histopathology with hematoxylin and eosin (H&E); immunostains are supportive, but not essential for diagnosis. (Hepatology 2018;68:113-126).",

author = "Elizabeth Brunt and Shinichi Aishima and Clavien, {Pierre Alain} and Kathryn Fowler and Zachary Goodman and Gregory Gores and Annette Gouw and Alex Kagen and David Klimstra and Mina Komuta and Fukuo Kondo and Rebecca Miksad and Masayuki Nakano and Yasuni Nakanuma and Irene Ng and Valerie Paradis and {Nyun Park}, Young and Alberto Quaglia and Massimo Roncalli and Tania Roskams and Michiie Sakamoto and Romil Saxena and Christine Sempoux and Claude Sirlin and Ashley Stueck and Swan Thung and Tsui, {W. M.S.} and Wang, {Xin Wei} and Aileen Wee and Hirohisa Yano and Matthew Yeh and Yoh Zen and Jessica Zucman-Rossi and Neil Theise",

note = "Publisher Copyright: {\textcopyright} 2018 by the American Association for the Study of Liver Diseases.",

year = "2018",

month = jul,

doi = "10.1002/hep.29789",

language = "English (US)",

volume = "68",

pages = "113--126",

journal = "Hepatology",

issn = "0270-9139",

publisher = "John Wiley and Sons Ltd",

number = "1",

}

TY - JOUR

T1 - cHCC-CCA

T2 - Consensus terminology for primary liver carcinomas with both hepatocytic and cholangiocytic differentation

AU - Brunt, Elizabeth

AU - Aishima, Shinichi

AU - Clavien, Pierre Alain

AU - Fowler, Kathryn

AU - Goodman, Zachary

AU - Gores, Gregory

AU - Gouw, Annette

AU - Kagen, Alex

AU - Klimstra, David

AU - Komuta, Mina

AU - Kondo, Fukuo

AU - Miksad, Rebecca

AU - Nakano, Masayuki

AU - Nakanuma, Yasuni

AU - Ng, Irene

AU - Paradis, Valerie

AU - Nyun Park, Young

AU - Quaglia, Alberto

AU - Roncalli, Massimo

AU - Roskams, Tania

AU - Sakamoto, Michiie

AU - Saxena, Romil

AU - Sempoux, Christine

AU - Sirlin, Claude

AU - Stueck, Ashley

AU - Thung, Swan

AU - Tsui, W. M.S.

AU - Wang, Xin Wei

AU - Wee, Aileen

AU - Yano, Hirohisa

AU - Yeh, Matthew

AU - Zen, Yoh

AU - Zucman-Rossi, Jessica

AU - Theise, Neil

PY - 2018/7

Y1 - 2018/7

N2 - Primary liver carcinomas with both hepatocytic and cholangiocytic differentiation have been referred to as “combined (or mixed) hepatocellular-cholangiocarcinoma.” These tumors, although described over 100 years ago, have attracted greater attention recently because of interest in possible stem cell origin and perhaps because of greater frequency and clinical recognition. Currently, because of a lack of common terminology in the literature, effective treatment and predictable outcome data have been challenging to accrue. This article represents a consensus document from an international community of pathologists, radiologists, and clinicians who have studied and reported on these tumors and recommends a working terminology for diagnostic and research approaches for further study and evaluation. Conclusion: It is recommended that diagnosis is based on routine histopathology with hematoxylin and eosin (H&E); immunostains are supportive, but not essential for diagnosis. (Hepatology 2018;68:113-126).

AB - Primary liver carcinomas with both hepatocytic and cholangiocytic differentiation have been referred to as “combined (or mixed) hepatocellular-cholangiocarcinoma.” These tumors, although described over 100 years ago, have attracted greater attention recently because of interest in possible stem cell origin and perhaps because of greater frequency and clinical recognition. Currently, because of a lack of common terminology in the literature, effective treatment and predictable outcome data have been challenging to accrue. This article represents a consensus document from an international community of pathologists, radiologists, and clinicians who have studied and reported on these tumors and recommends a working terminology for diagnostic and research approaches for further study and evaluation. Conclusion: It is recommended that diagnosis is based on routine histopathology with hematoxylin and eosin (H&E); immunostains are supportive, but not essential for diagnosis. (Hepatology 2018;68:113-126).

UR - http://www.scopus.com/inward/record.url?scp=85044599045&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044599045&partnerID=8YFLogxK

U2 - 10.1002/hep.29789

DO - 10.1002/hep.29789

M3 - Article

C2 - 29360137

AN - SCOPUS:85044599045

SN - 0270-9139

VL - 68

SP - 113

EP - 126

JO - Hepatology

JF - Hepatology

IS - 1

ER -

cHCC-CCA: Consensus terminology for primary liver carcinomas with both hepatocytic and cholangiocytic differentation

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this